Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05942001 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Prostate Cancer

Interventions

DRUG: HRS-5041

Sponsor

Jiangsu HengRui Medicine Co., Ltd.